TWI848030B - Ｃｄ７０組合治療 - Google Patents

Ｃｄ７０組合治療 Download PDF

Info

Publication number
TWI848030B
TWI848030B TW108146057A TW108146057A TWI848030B TW I848030 B TWI848030 B TW I848030B TW 108146057 A TW108146057 A TW 108146057A TW 108146057 A TW108146057 A TW 108146057A TW I848030 B TWI848030 B TW I848030B
Authority
TW
Taiwan
Prior art keywords
combination
antibody
antigen
binding fragment
bcl
Prior art date
Application number
TW108146057A
Other languages
English (en)
Chinese (zh)
Other versions
TW202038958A (zh
Inventor
范 盧克 羅姆
德 漢斯 哈德
尼古拉斯 勒平
薩姆森 馮
卡斯滕 里瑟
阿德里安 奧克森貝恩
Original Assignee
比利時商阿根思公司
伯爾尼大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820582.3A external-priority patent/GB201820582D0/en
Priority claimed from GBGB1911007.1A external-priority patent/GB201911007D0/en
Priority claimed from GBGB1917701.3A external-priority patent/GB201917701D0/en
Application filed by 比利時商阿根思公司, 伯爾尼大學 filed Critical 比利時商阿根思公司
Publication of TW202038958A publication Critical patent/TW202038958A/zh
Application granted granted Critical
Publication of TWI848030B publication Critical patent/TWI848030B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW108146057A 2018-12-18 2019-12-16 Ｃｄ７０組合治療 TWI848030B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1820582.3 2018-12-18
GBGB1820582.3A GB201820582D0 (en) 2018-12-18 2018-12-18 CD70 combination therapy
GB1911007.1 2019-08-01
GBGB1911007.1A GB201911007D0 (en) 2019-08-01 2019-08-01 CD70 combination therapy
GB1917701.3 2019-12-04
GBGB1917701.3A GB201917701D0 (en) 2019-12-04 2019-12-04 CD70 Combination therapy

Publications (2)

Publication Number Publication Date
TW202038958A TW202038958A (zh) 2020-11-01
TWI848030B true TWI848030B (zh) 2024-07-11

Family

ID=69104399

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108146057A TWI848030B (zh) 2018-12-18 2019-12-16 Ｃｄ７０組合治療

Country Status (21)

Country Link
US (3) US11712468B2 (https=)
EP (2) EP3890740B1 (https=)
JP (2) JP7565921B2 (https=)
KR (1) KR20210106428A (https=)
CN (2) CN113226317B (https=)
AU (2) AU2019409936B2 (https=)
BR (1) BR112021011684A2 (https=)
CA (1) CA3117282A1 (https=)
DK (1) DK3890740T3 (https=)
ES (1) ES2941638T3 (https=)
FI (1) FI3890740T3 (https=)
HU (1) HUE061710T2 (https=)
IL (1) IL284015B2 (https=)
LT (1) LT3890740T (https=)
MX (1) MX2021007350A (https=)
PL (1) PL3890740T3 (https=)
PT (1) PT3890740T (https=)
SG (1) SG11202105197UA (https=)
TW (1) TWI848030B (https=)
UY (1) UY38511A (https=)
WO (1) WO2020127503A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
BR112021025537A2 (pt) 2019-06-20 2022-03-03 Celgene Quanticel Res Inc Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2022043538A1 (en) * 2020-08-29 2022-03-03 argenx BV Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
CN117642157A (zh) * 2021-03-19 2024-03-01 伊尔治疗学股份有限公司 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物
CA3222020A1 (en) * 2021-07-21 2023-01-26 Emory University Bak activators, pharmaceutical compositions, and uses in treating cancer
TW202319400A (zh) * 2021-09-02 2023-05-16 瑞士商赫孚孟拉羅股份公司 用於治療aml之抗體
US20240426824A1 (en) * 2021-11-03 2024-12-26 Stefan E. HUBNER Methods relating to treatment of acute myeloid leukemia
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
CN114949230B (zh) * 2022-06-13 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN117771177A (zh) * 2023-08-02 2024-03-29 首都医科大学附属北京儿童医院 维奈克拉自微乳化释药系统及其制备方法和应用
WO2025181039A1 (en) * 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2025212259A1 (en) * 2024-04-02 2025-10-09 Board Of Regents, The University Of Texas System Methods for prognosing and treating acute myeloid leukemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2002351828A1 (en) 2001-11-05 2003-05-19 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
ES2394018T3 (es) 2001-11-27 2013-01-15 Ucb Pharma S.A. Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
JP5097707B2 (ja) 2006-07-24 2012-12-12 千田建設株式会社 金属線材のスケール除去方法と装置
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
CN101854924A (zh) 2007-11-05 2010-10-06 诺瓦提斯公司 测量wnt活化以及治疗wnt相关癌症的方法和组合物
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
US20110190157A1 (en) 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2987487B1 (en) 2009-08-10 2020-10-07 Samumed, LLC Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US20120178111A1 (en) 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EP2520589B1 (en) 2009-12-29 2018-11-07 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
WO2013138586A1 (en) 2012-03-15 2013-09-19 Janssen Biotech, Inc. Human anti-cd27 antibodies, methods and uses
HK1204578A1 (en) 2012-03-21 2015-11-27 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
WO2013177420A2 (en) 2012-05-23 2013-11-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
CN106188045B (zh) 2012-06-15 2018-01-16 广州源生医药科技有限公司 作为wnt信号传导抑制剂的化合物、组合物及其应用
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014100772A1 (en) 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
RS56169B1 (sr) 2013-02-14 2017-11-30 Bristol Myers Squibb Co Jedinjenja tubulisina, metode pripreme i primena
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
WO2017044752A1 (en) 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
AU2016349279A1 (en) * 2015-11-03 2018-05-10 Board Of Regents, The University Of Texas System Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
EP3426655A1 (en) 2016-03-10 2019-01-16 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
CN109563096A (zh) 2016-06-09 2019-04-02 雷迪博士实验室有限公司 固体形式的维奈托克和用于制备维奈托克的方法
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
CN107648185A (zh) 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
WO2018029711A2 (en) 2016-08-12 2018-02-15 Mylan Laboratories Limited Process for the preparation of venetoclax
US10800777B2 (en) 2016-10-14 2020-10-13 Mylan Laboratories Limited Polymorphic forms of VENCLEXTA
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
CZ201769A3 (cs) 2017-02-06 2018-08-15 Zentiva, K.S. Pevné formy venetoclaxu
WO2018157803A1 (zh) 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) * 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors

Also Published As

Publication number Publication date
TW202038958A (zh) 2020-11-01
FI3890740T3 (fi) 2023-05-24
HUE061710T2 (hu) 2023-08-28
EP4218761A1 (en) 2023-08-02
CN113226317B (zh) 2022-08-16
BR112021011684A2 (pt) 2021-11-30
US20200222532A1 (en) 2020-07-16
IL284015A (en) 2021-08-31
EP3890740A1 (en) 2021-10-13
KR20210106428A (ko) 2021-08-30
US11712468B2 (en) 2023-08-01
DK3890740T3 (da) 2023-05-08
CN113226317A (zh) 2021-08-06
PT3890740T (pt) 2023-05-15
US20250152707A1 (en) 2025-05-15
CN115920034A (zh) 2023-04-07
LT3890740T (lt) 2023-03-27
JP7565921B2 (ja) 2024-10-11
AU2019409936B2 (en) 2025-09-11
JP2022515077A (ja) 2022-02-17
JP2025000862A (ja) 2025-01-07
IL284015B2 (en) 2024-10-01
CA3117282A1 (en) 2020-06-25
UY38511A (es) 2020-07-31
CN115920034B (zh) 2026-01-02
ES2941638T3 (es) 2023-05-24
US20240033353A1 (en) 2024-02-01
AU2019409936A1 (en) 2021-05-27
WO2020127503A1 (en) 2020-06-25
PL3890740T3 (pl) 2023-07-24
IL284015B1 (en) 2024-06-01
AU2025259981A1 (en) 2025-11-20
SG11202105197UA (en) 2021-07-29
MX2021007350A (es) 2021-09-21
EP3890740B1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
TWI848030B (zh) Ｃｄ７０組合治療
KR102799514B1 (ko) 급성 골수성 백혈병(acute myeloid leukaemia) 치료를 위한 항 cd70-항체 argx-110의 용도
KR20140054186A (ko) 암의 치료 및/또는 예방용 의약 조성물
US20240182590A1 (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
KR20250175330A (ko) 항체-약물 콘주게이트와 다른 약제의 조합
HK40097470A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40091007A (zh) 用於治疗急性骨髓性白血病的cd70 和bcl-2 抑制剂的组合疗法
HK40052961B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40052961A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
EA049354B1 (ru) Cd70 и венетоклакс, ингибитор bcl-2, комбинированная терапия для лечения острого миелоидного лейкоза
HK40049607A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40049607B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
KR20230083296A (ko) 암 치료용 의약
HK40089820A (zh) 治疗对bcl-2抑制剂具有降低的敏感性的患者的方法
US20250195653A1 (en) Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
EA050897B1 (ru) Способ лечения пациентов с пониженной чувствительностью к ингибитору bcl-2